Neurocrine Biosciences Director Files Form 144 for 300 Shares

Executive Summary

On October 30, 2026, George Morrow, a Director at Neurocrine Biosciences, Inc. ($NBIX), filed a Form 144 notice disclosing an intention to sell 300 shares of common stock with an aggregate market value of $43,914.00 through Morgan Stanley Smith Barney LLC.

Key Transaction Details

• Insider: George Morrow (Director)
• Securities to be Sold: 300 Common shares
• Estimated Market Value: $43,914.00 (~$146.38 per share)
• Shares Outstanding: 101,649,181 shares
• Acquisition Nature: Exercise of stock options on October 30, 2026, paid in cash
• Plan Adoption: The sale is being executed under a Rule 10b5-1 trading plan established on May 26, 2026

Market Impact & Significance

The proposed transaction represents an immaterial fraction of Neurocrine Biosciences' total outstanding shares (<0.001%) and a modest dollar value of ~$44k. Given the transaction size and the fact that it is being conducted pursuant to a pre-arranged Rule 10b5-1 plan, it carries minimal trading significance and poses no directional signal for the company's stock.